Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Atrion Reports Third Quarter Results

ATRI

ALLEN, Texas, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that for the third quarter of 2017 revenues totaled $37.9 million compared with $37.8 million for the same period in 2016. Operating income for the just-ended quarter was $11.5 million compared to $11.0 million in the same period of 2016. Net income for the third quarter was $8.0 million as compared to $7.6 million in last year’s third quarter.  On a diluted per share basis, earnings for the period increased to $4.29 as compared to $4.10 for the same quarter of last year.

Commenting on the results for the third quarter compared to the same period of 2016, David Battat, President and CEO, said, “We are very pleased with our Cardiovascular revenues, which were up 13% or $1.4 million. Our overall sales were essentially flat due to lower sales in other product areas, most notably in Ophthalmology which continued to show the impact of a previously disclosed interruption in orders from a customer which has withdrawn its product from the market pending resolution of a quality issue unrelated to the component we supply.” Mr. Battat continued, “Operational improvements contributed to an increase in gross profit margins to 49% compared to 47% in the same quarter in 2016. Operating income, net income and diluted earnings per share all increased by 5% compared to last year’s quarter.”  Mr. Battat added, “During the quarter our cash and short and long term investments increased by $12.8 million to a total of $70.1 million as of September 30, 2017.”

Atrion Corporation develops and manufactures products primarily for medical applications.  The Company’s website is www.atrioncorp.com.

Contact:
Jeffery Strickland
Vice President and Chief Financial Officer
(972) 390-9800


ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2017       2016       2017       2016  
Revenues $   37,903     $   37,835     $   112,571     $   110,193  
Cost of goods sold     19,498         20,211         57,841         57,789  
  Gross profit     18,405         17,624         54,730         52,404  
Operating expenses     6,926         6,648         21,749         20,889  
  Operating income     11,479         10,976         32,981         31,515  
               
Interest and dividend income     287         106         806         315  
Other income     --         1           1           (309 )
Income before income taxes     11,766         11,083         33,788         31,521  
Income tax provision     (3,795 )       (3,469 )       (5,841 )       (9,511 )
  Net income $     7,971     $     7,614     $   27,947     $   22,010  
               
Income per basic share $     4.30     $     4.17     $     15.16     $     12.07  
               
Weighted average basic shares   outstanding     1,852         1,825         1,844         1,823  
               
               
Income per diluted share $     4.29     $     4.10     $   15.06     $   11.86  
               
Weighted average diluted shares   outstanding     1,857         1,858         1,856         1,856  


ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)

  Sept. 30,   Dec. 31,
ASSETS  2017    2016
  (Unaudited)    
Current assets:      
  Cash and cash equivalents $   20,995   $   20,022
  Short-term investments     38,959       24,080
    Total cash and short-term investments     59,954       44,102
  Accounts receivable     19,585       17,166
  Inventories     29,924       29,015
  Prepaid expenses and other     3,001       3,181
      Total current assets     112,464       93,464
Long-term investments     10,112       9,945
Property, plant and equipment, net     66,518       65,265
Other assets     13,032       13,268
       
  $   202,126   $   181,942
       
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
       
  Current liabilities     12,694       9,073
  Line of credit     --       --
  Other non-current liabilities     10,981       9,881
  Stockholders’ equity     178,451       162,988
       
  $   202,126   $   181,942